A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03616912

Recruitment Status : Terminated (Study terminated due to insufficient evidence to support a positive benefit: risk ratio. Safety findings were consistent with previously published OLUMIANT data)

First Posted : August 6, 2018

Last Update Posted : May 13, 2022

Sponsor:

Collaborator:

Incyte Corporation

Information provided by (Responsible Party):

Eli Lilly and Company

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	November 1, 2021
Actual Study Completion Date :	March 9, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3:CD007478. doi: 10.1002/14651858.CD007478.pub2.

To Top